Arthur Wong examines AbbVie (ABBV) following the healthcare company's earnings beat in its 3Q. He discusses the pharmaceutical pipeline, its oncology segment and current offerings like its autoimmune medication Humira. Arthur discusses the relationship between weaker consumer sentiment and patients willingness to spend on expensive medical treatments. He also talks about the industry trend to negotiate lower drug-costs with the Trump administration. He says tariffs and "MFN" Pricing (Most Favored Nation) are the biggest headwinds for pharmaceutical companies.